Insider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) Insider Sells $406,150.20 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 5,490 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Gilead Sciences Stock Performance

GILD stock opened at $73.78 on Friday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The firm has a market cap of $91.92 billion, a price-to-earnings ratio of 204.94, a PEG ratio of 3.37 and a beta of 0.18. The business’s fifty day simple moving average is $70.80 and its two-hundred day simple moving average is $70.31. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.17%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 2.6% during the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock valued at $8,404,161,000 after acquiring an additional 2,910,147 shares in the last quarter. Capital World Investors grew its stake in Gilead Sciences by 1.4% in the first quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company’s stock worth $6,189,435,000 after purchasing an additional 1,133,281 shares in the last quarter. Capital Research Global Investors increased its holdings in Gilead Sciences by 2.7% during the 1st quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock worth $4,486,296,000 after purchasing an additional 1,589,240 shares during the period. Wellington Management Group LLP raised its position in Gilead Sciences by 14.4% during the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after purchasing an additional 2,350,550 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Gilead Sciences in the 4th quarter worth $1,301,624,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research reports. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Oppenheimer reiterated an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research report on Friday, April 19th. Truist Financial boosted their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $70.00 price target on shares of Gilead Sciences in a report on Friday, August 9th. Finally, Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research note on Monday, July 8th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $81.94.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.